The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
Official Title: Zevalin® (Ibritumomab Tiuxetan) Followed by Rituxan® (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
Study ID: NCT00168727
Brief Summary: The purpose of this study is to determine the safety and effectiveness of a treatment regimen using Zevalin® plus Rituxan® for patients who have low grade Non-Hodgkin's Lymphoma (NHL) or relapsed Non-Hodgkin's lymphoma and have been previously treated. This study will use an experimental scheduling regimen. No chemotherapy will be used in this study.
Detailed Description: The objective of this study is to determine overall response rate, event-free survival, time-to-progression, time-to-next-therapy, and freedom-from-relapse in patients with low-grade lymphoma in first or second relapse treated with Zevalin followed by 2 years of Rituxan maintenance therapy in a multicenter, community-based setting, as well as evaluate relative response rates in populations with and without prior rituximab therapy, in first versus second relapse, and with and without bulky (\> 5 cm in greatest diameter) disease. To meet the initial trial enrollment goal of 300 patients over two years, 42 total sites were activated. The study has subsequently closed to accrual. Currently 8 sites remain active to follow the 12 subjects enrolled in the past year.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Loma Linda University, Loma Linda, California, United States
North County Oncology, Oceanside, California, United States
Medical Specialists of Fairfield, Fairfield, Connecticut, United States
Queens Hospital, Honolulu, Hawaii, United States
Northwest Oncology and Hematology, Elk Grove Village, Illinois, United States
Horizon Oncolgy Center, Lafayette, Indiana, United States
Specialists in Hematology/Oncology, Saint Louis, Missouri, United States
Presbyterian Hospital Cancer Center, Charlotte, North Carolina, United States
Name: Wayne Saville
Affiliation: Biogen
Role: STUDY_DIRECTOR